Posted by Michael Wonder on 12 Feb 2026
99mTc-maraciclatide granted FDA fast track designation for the visualisation of inflammation in interstitial lung disease
12 February 2026 - Serac Healthcare announced today that the US FDA has granted fast track designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualisation of inflammation in the lungs of patients with known and suspected interstitial lung disease.
99mTc-maraciclatide is a radio-labelled tracer which binds with high affinity to αvβ3 integrin, a cell-adhesion molecule which is up-regulated in vascular endothelial cells during angiogenesis, a key biological process that occurs during inflammation.
